Etty Kruzel-Davila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Etty Kruzel-Davila has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Karl Skorecki
The Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology , Haifa
2 shared publications- Karl Skorecki
Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel
2 shared publications - Adebowale Dele Ademola
Department of Paediatrics, University College Hospital, Ibadan, Oyo State, Nigeria.
1 shared publication - Akinlolu Ojo
University of Kansas School of Medicine, Kansas City, Kansas, USA
1 shared publication - Alexander Kwadwo Nyarko
Department of Pharmacology and Toxicology, School of Pharmacy, University of Ghana, Accra, Ghana
1 shared publication Alla Shnaider
Department of Nephrology, Soroka University Medical Center , Beer-Sheva
1 shared publication
Latest Publications
- Open Access
Peripherality and Indicators of Nutrition Status in Jewish Israeli Hemodialysis Patients: A Cross-Sectional Study
Background: Geographic peripherality in Israel is linked to poorer health outcomes and may disproportionately affect patients requiring chronic therapies such as hemodialysis (HD). Though malnutrition and inflammation are strong predictors of morbidity and mortality in HD patients, regional differences in nutritional status and dietary adherence are unclear. Objectives: To examine the association between peripherality and malnutrition risk, dietary intake, and adherence to nutrition guidelines among Jewish Israeli adults on HD. Methods: In this multi-center, cross-sectional study, 154 adult Jewish HD patients were recruited from the northern periphery (n = 66) and central regions of Israel (n = 88). Demographic, clinical, laboratory, and anthropometric data were obtained from medical records. Nutrient intake was assessed using the multi-pass 24 h dietary recall method. Malnutrition risk was classified using BMI and serum albumin; the C-reactive protein-to-albumin ratio (CAR) was also calculated. Adherence to International Society of Renal Nutrition and Metabolism (ISRNM) dietary guidelines was evaluated. Between-group comparisons and multivariable regression analyses were conducted. Results: Overall, participant characteristics were similar between groups; however, coronary heart disease prevalence and dialysis vintage were higher in the periphery. Participants from the periphery had lower serum albumin, blood urea nitrogen, hemoglobin, and blood pressure, but higher LDL cholesterol. Sodium intake was significantly higher and adherence to ISRNM sodium guidelines markedly lower in the periphery. In multivariable analysis, peripherality reduced the odds of meeting sodium recommendations by 92.8%. Adherence to energy and protein guidelines was low in both groups. Nearly half of participants had some level of elevated malnutrition risk using the categorized variable, and an overall difference in the categories of malnutrition risk was detected, driven by the increase in the moderate risk category in the periphery. The composite malnutrition risk variable (any increase in risk vs. no increase in risk) did not differ by peripherality. Peripherality was independently associated with higher percent ideal body weight (%IBW), but not with CAR. Conclusions: Peripherality among Jewish Israeli HD patients is associated with differences in nutrition biomarkers, cardiovascular burden, and dietary adherence, especially sodium intake. Interventions considering peripherality should be explored.
Open AccessPeripherality and Indicators of Nutrition Status in Jewish Israeli Hemodialysis Patients: A Cross-Sectional Study
Background: Geographic peripherality in Israel is linked to poorer health outcomes and may disproportionately affect patients requiring chronic therapies such as hemodialysis (HD). Though malnutrition and inflammation are strong predictors of morbidity and mortality in HD patients, regional differences in nutritional status and dietary adherence are unclear. Objectives: To examine the association between peripherality and malnutrition risk, dietary intake, and adherence to nutrition guidelines among Jewish Israeli adults on HD. Methods: In this multi-center, cross-sectional study, 154 adult Jewish HD patients were recruited from the northern periphery (n = 66) and central regions of Israel (n = 88). Demographic, clinical, laboratory, and anthropometric data were obtained from medical records. Nutrient intake was assessed using the multi-pass 24 h dietary recall method. Malnutrition risk was classified using BMI and serum albumin; the C-reactive protein-to-albumin ratio (CAR) was also calculated. Adherence to International Society of Renal Nutrition and Metabolism (ISRNM) dietary guidelines was evaluated. Between-group comparisons and multivariable regression analyses were conducted. Results: Overall, participant characteristics were similar between groups; however, coronary heart disease prevalence and dialysis vintage were higher in the periphery. Participants from the periphery had lower serum albumin, blood urea nitrogen, hemoglobin, and blood pressure, but higher LDL cholesterol. Sodium intake was significantly higher and adherence to ISRNM sodium guidelines markedly lower in the periphery. In multivariable analysis, peripherality reduced the odds of meeting sodium recommendations by 92.8%. Adherence to energy and protein guidelines was low in both groups. Nearly half of participants had some level of elevated malnutrition risk using the categorized variable, and an overall difference in the categories of malnutrition risk was detected, driven by the increase in the moderate risk category in the periphery. The composite malnutrition risk variable (any increase in risk vs. no increase in risk) did not differ by peripherality. Peripherality was independently associated with higher percent ideal body weight (%IBW), but not with CAR. Conclusions: Peripherality among Jewish Israeli HD patients is associated with differences in nutrition biomarkers, cardiovascular burden, and dietary adherence, especially sodium intake. Interventions considering peripherality should be explored.
- Open Access
- 21 January 2025
- Published by Springer Nature
Evaluating the effect of hemodialysis modality on inflammation
- 21 January 2025
- Published by Springer Nature
Open AccessEvaluating the effect of hemodialysis modality on inflammation
- Open Access
- 6 December 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (2) , sfae397
Multiethnic prevalence of the APOL1 G1 and G2 variants among the Israeli dialysis population
Background and hypothesis: The two apolipoprotein L1 (APOL1) variants, G1 and G2, are common in populations of sub-Saharan African ancestry. Individuals with two of these alleles (G1 or G2) have an increased risk for a spectrum of non-diabetic chronic kidney diseases. However, these variants are typically not observed outside of populations that self-identify as current continental Africans or having clear recent African ancestry such as, most notably, African Americans, and other large population groups in the Americas and several European countries. We hypothesized that the diverse ethnic groups within the Israeli population may exhibit varying levels of recent African ancestry. Therefore, it is plausible that APOL1 risk alleles might be present even in individuals who do not self-identify as being of sub-Saharan African descent. Methods: We non-selectively screened people with kidney failure across Israel for APOL1 risk variants using restriction fragment length polymorphism. Results: We recruited 1744 individuals from 38 dialysis units in Israel. We identified eight patients of Moroccan Jewish, Bedouin, or Muslim Arab ancestry, who carry at least one G1 or G2 allele. None of the eight patients carried the protective APOL1 p.N264K variant. Furthermore, despite all Bedouin individuals being G2 heterozygous, the G2 minor allele frequency was significantly enriched in kidney failure cases compared to ethnically matched controls (P = .006). Conclusions: These findings show that APOL1 G1 and G2 allelic variants are present in populations previously not appreciated to possess recent sub-Saharan ancestry and suggest that a single G2 risk variant may confer increased risk for chronic kidney disease in certain population contexts.
- 6 December 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (2) , sfae397
Open AccessMultiethnic prevalence of the APOL1 G1 and G2 variants among the Israeli dialysis population
Background and hypothesis: The two apolipoprotein L1 (APOL1) variants, G1 and G2, are common in populations of sub-Saharan African ancestry. Individuals with two of these alleles (G1 or G2) have an increased risk for a spectrum of non-diabetic chronic kidney diseases. However, these variants are typically not observed outside of populations that self-identify as current continental Africans or having clear recent African ancestry such as, most notably, African Americans, and other large population groups in the Americas and several European countries. We hypothesized that the diverse ethnic groups within the Israeli population may exhibit varying levels of recent African ancestry. Therefore, it is plausible that APOL1 risk alleles might be present even in individuals who do not self-identify as being of sub-Saharan African descent. Methods: We non-selectively screened people with kidney failure across Israel for APOL1 risk variants using restriction fragment length polymorphism. Results: We recruited 1744 individuals from 38 dialysis units in Israel. We identified eight patients of Moroccan Jewish, Bedouin, or Muslim Arab ancestry, who carry at least one G1 or G2 allele. None of the eight patients carried the protective APOL1 p.N264K variant. Furthermore, despite all Bedouin individuals being G2 heterozygous, the G2 minor allele frequency was significantly enriched in kidney failure cases compared to ethnically matched controls (P = .006). Conclusions: These findings show that APOL1 G1 and G2 allelic variants are present in populations previously not appreciated to possess recent sub-Saharan ancestry and suggest that a single G2 risk variant may confer increased risk for chronic kidney disease in certain population contexts.
- Open Access
- 27 August 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
HIV Viremia Is Associated With APOL1 Variants and Reduced JC-Viruria
Variants in the Apolipoprotein L1 (APOL1) gene (G1-rs60910145, rs73885319, G2-rs71785313) are common in Africans and in individuals of recent African ancestry and are associated with an increased risk of non-diabetic chronic kidney disease (CKD) and in particular of HIV associated nephropathy (HIVAN). In light of the significantly increased risk of HIVAN in carriers of two APOL1 risk alleles, a role in HIV infectivity has been postulated in the mechanism of APOL1 associated kidney disease. Herein, we aim to explore the association between HIV viremia and APOL1 genotype. In addition, we investigated interaction between BK and JC viruria, CKD and HIV viremia. A total of 199 persons living with HIV/AIDS (comprising 82 CKD cases and 117 controls) from among the participants in the ongoing Human Heredity and Health in Africa (H3Africa) Kidney Disease Research Network case control study have been recruited. The two APOL1 renal risk alleles (RRA) genotypes were associated with a higher risk of CKD (OR 12.6, 95% CI 3.89–40.8, p < 0.0001). Even a single APOL1 RRA was associated with CKD risk (OR 4.42, 95% CI 1.49–13.15, p = 0.007). The 2 APOL1 RRA genotypes were associated with an increased probability of having HIV viremia (OR 2.37 95% CI 1.0–5.63, p = 0.05). HIV viremia was associated with increased CKD risk (OR 7.45, 95% CI 1.66–33.35, P = 0.009) and with a significant reduction of JC virus urine shedding (OR 0.35, 95% CI 0.12–0.98, p = 0.046). In contrast to prior studies, JC viruria was not associated with CKD but was restricted in patients with HIV viremia, regardless of CKD status. These findings suggest a role of APOL1 variants in HIV infectivity and emphasize that JC viruria can serve as biomarker for innate immune system activation.
- 27 August 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Open AccessHIV Viremia Is Associated With APOL1 Variants and Reduced JC-Viruria
Variants in the Apolipoprotein L1 (APOL1) gene (G1-rs60910145, rs73885319, G2-rs71785313) are common in Africans and in individuals of recent African ancestry and are associated with an increased risk of non-diabetic chronic kidney disease (CKD) and in particular of HIV associated nephropathy (HIVAN). In light of the significantly increased risk of HIVAN in carriers of two APOL1 risk alleles, a role in HIV infectivity has been postulated in the mechanism of APOL1 associated kidney disease. Herein, we aim to explore the association between HIV viremia and APOL1 genotype. In addition, we investigated interaction between BK and JC viruria, CKD and HIV viremia. A total of 199 persons living with HIV/AIDS (comprising 82 CKD cases and 117 controls) from among the participants in the ongoing Human Heredity and Health in Africa (H3Africa) Kidney Disease Research Network case control study have been recruited. The two APOL1 renal risk alleles (RRA) genotypes were associated with a higher risk of CKD (OR 12.6, 95% CI 3.89–40.8, p < 0.0001). Even a single APOL1 RRA was associated with CKD risk (OR 4.42, 95% CI 1.49–13.15, p = 0.007). The 2 APOL1 RRA genotypes were associated with an increased probability of having HIV viremia (OR 2.37 95% CI 1.0–5.63, p = 0.05). HIV viremia was associated with increased CKD risk (OR 7.45, 95% CI 1.66–33.35, P = 0.009) and with a significant reduction of JC virus urine shedding (OR 0.35, 95% CI 0.12–0.98, p = 0.046). In contrast to prior studies, JC viruria was not associated with CKD but was restricted in patients with HIV viremia, regardless of CKD status. These findings suggest a role of APOL1 variants in HIV infectivity and emphasize that JC viruria can serve as biomarker for innate immune system activation.
- 1 March 2021
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 320 (3) , L422-L429
Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease
The unique clinical features of COVID-19 disease present a formidable challenge in the understanding of its pathogenesis. Within a very short time, our knowledge regarding basic physiological pathways that participate in SARS-CoV-2 invasion and subsequent organ damage have been dramatically expanded. In particular, we now better understand the complexity of the renin-angiotensin-aldosterone system (RAAS) and the important role of angiotensin converting enzyme (ACE)-2 in viral binding. Furthermore, the critical role of its major product, angiotensin (Ang)-(1–7), in maintaining microcirculatory balance and in the control of activated proinflammatory and procoagulant pathways, generated in this disease, have been largely clarified. The kallikrein-bradykinin (BK) system and chymase are intensively interwoven with RAAS through many pathways with complex reciprocal interactions. Yet, so far, very little attention has been paid to a possible role of these physiological pathways in the pathogenesis of COVID-19 disease, even though BK and chymase exert many physiological changes characteristic to this disorder. Herein, we outline the current knowledge regarding the reciprocal interactions of RAAS, BK, and chymase that are probably turned-on in COVID-19 disease and participate in its clinical features. Interventions affecting these systems, such as the inhibition of chymase or blocking BKB1R/BKB2R, might be explored as potential novel therapeutic strategies in this devastating disorder.
- 1 March 2021
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 320 (3) , L422-L429
Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease
The unique clinical features of COVID-19 disease present a formidable challenge in the understanding of its pathogenesis. Within a very short time, our knowledge regarding basic physiological pathways that participate in SARS-CoV-2 invasion and subsequent organ damage have been dramatically expanded. In particular, we now better understand the complexity of the renin-angiotensin-aldosterone system (RAAS) and the important role of angiotensin converting enzyme (ACE)-2 in viral binding. Furthermore, the critical role of its major product, angiotensin (Ang)-(1–7), in maintaining microcirculatory balance and in the control of activated proinflammatory and procoagulant pathways, generated in this disease, have been largely clarified. The kallikrein-bradykinin (BK) system and chymase are intensively interwoven with RAAS through many pathways with complex reciprocal interactions. Yet, so far, very little attention has been paid to a possible role of these physiological pathways in the pathogenesis of COVID-19 disease, even though BK and chymase exert many physiological changes characteristic to this disorder. Herein, we outline the current knowledge regarding the reciprocal interactions of RAAS, BK, and chymase that are probably turned-on in COVID-19 disease and participate in its clinical features. Interventions affecting these systems, such as the inhibition of chymase or blocking BKB1R/BKB2R, might be explored as potential novel therapeutic strategies in this devastating disorder.
- Open Access
- 3 July 2017
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 6
The double-edged sword of evolution
African trypanosomiasis is a disease caused by trypanosome parasites that affects humans and other animals in sub-Saharan Africa. In humans, the disease manifests itself as sleeping sickness, and it can be fatal if untreated. Previous research has shown that a protein called APOL1 (short for Apolipoprotein 1) protects against many different species of trypanosome parasites in humans (Vanhamme et al., 2003). However, two subspecies have evolved independent mechanisms to become resistant to APOL1: Trypanosoma brucei rhodesiense, which predominates in East Africa, and Trypanosoma brucei gambiense, which is more common in West Africa (Uzureau et al., 2013; Pays et al., 2014).
- 3 July 2017
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 6
Open AccessThe double-edged sword of evolution
African trypanosomiasis is a disease caused by trypanosome parasites that affects humans and other animals in sub-Saharan Africa. In humans, the disease manifests itself as sleeping sickness, and it can be fatal if untreated. Previous research has shown that a protein called APOL1 (short for Apolipoprotein 1) protects against many different species of trypanosome parasites in humans (Vanhamme et al., 2003). However, two subspecies have evolved independent mechanisms to become resistant to APOL1: Trypanosoma brucei rhodesiense, which predominates in East Africa, and Trypanosoma brucei gambiense, which is more common in West Africa (Uzureau et al., 2013; Pays et al., 2014).